Zacks Research Issues Pessimistic Outlook for BAX Earnings

Baxter International Inc. (NYSE:BAX - Free Report) - Research analysts at Zacks Research lowered their Q3 2025 EPS estimates for shares of Baxter International in a report released on Thursday, May 22nd. Zacks Research analyst I. Bandyopadhyay now expects that the medical instruments supplier will post earnings per share of $0.63 for the quarter, down from their prior forecast of $0.66. The consensus estimate for Baxter International's current full-year earnings is $2.48 per share. Zacks Research also issued estimates for Baxter International's Q2 2026 earnings at $0.61 EPS, Q4 2026 earnings at $0.77 EPS and Q1 2027 earnings at $0.57 EPS.

Baxter International (NYSE:BAX - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $0.62 earnings per share for the quarter, topping analysts' consensus estimates of $0.48 by $0.14. The firm had revenue of $2.63 billion during the quarter, compared to analysts' expectations of $2.59 billion. Baxter International had a negative net margin of 5.05% and a positive return on equity of 16.67%. Baxter International's quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.65 EPS.

A number of other brokerages have also recently weighed in on BAX. Wells Fargo & Company decreased their price target on shares of Baxter International from $36.00 to $33.00 and set an "equal weight" rating for the company in a research note on Friday, May 2nd. Argus upgraded shares of Baxter International from a "hold" rating to a "buy" rating in a research note on Monday, February 24th. JPMorgan Chase & Co. reduced their target price on shares of Baxter International from $38.00 to $36.00 and set a "neutral" rating for the company in a research note on Friday, February 21st. Barclays raised their target price on shares of Baxter International from $39.00 to $41.00 and gave the stock an "overweight" rating in a research note on Monday, March 10th. Finally, Morgan Stanley reduced their target price on shares of Baxter International from $30.00 to $28.00 and set an "underweight" rating for the company in a research note on Monday, May 5th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company. According to MarketBeat.com, Baxter International presently has a consensus rating of "Hold" and a consensus target price of $37.25.

Baxter International Stock Performance

NYSE:BAX traded down $0.33 during trading hours on Monday, reaching $30.54. 2,723,562 shares of the company's stock were exchanged, compared to its average volume of 4,474,260. The firm has a market capitalization of $15.67 billion, a price-to-earnings ratio of -23.86, a P/E/G ratio of 0.93 and a beta of 0.63. The company has a 50-day moving average of $30.65 and a 200 day moving average of $31.56. The company has a quick ratio of 1.09, a current ratio of 1.43 and a debt-to-equity ratio of 1.31. Baxter International has a 1-year low of $26.25 and a 1-year high of $40.49.

Hedge Funds Weigh In On Baxter International

A number of large investors have recently made changes to their positions in the stock. Anchor Investment Management LLC increased its holdings in shares of Baxter International by 3.4% in the 1st quarter. Anchor Investment Management LLC now owns 21,164 shares of the medical instruments supplier's stock valued at $724,000 after purchasing an additional 701 shares in the last quarter. RNC Capital Management LLC increased its holdings in shares of Baxter International by 74.0% in the 1st quarter. RNC Capital Management LLC now owns 136,048 shares of the medical instruments supplier's stock valued at $4,657,000 after purchasing an additional 57,855 shares in the last quarter. Sciencast Management LP purchased a new position in shares of Baxter International in the 1st quarter valued at about $356,000. Amundi increased its holdings in shares of Baxter International by 9.5% in the 1st quarter. Amundi now owns 1,444,705 shares of the medical instruments supplier's stock valued at $45,292,000 after purchasing an additional 125,431 shares in the last quarter. Finally, Gamco Investors INC. ET AL increased its holdings in shares of Baxter International by 19.4% in the 1st quarter. Gamco Investors INC. ET AL now owns 188,673 shares of the medical instruments supplier's stock valued at $6,458,000 after purchasing an additional 30,700 shares in the last quarter. Hedge funds and other institutional investors own 90.19% of the company's stock.

Baxter International Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, July 1st. Stockholders of record on Friday, May 30th will be issued a $0.17 dividend. The ex-dividend date of this dividend is Friday, May 30th. This represents a $0.68 dividend on an annualized basis and a dividend yield of 2.23%. Baxter International's dividend payout ratio is presently -61.82%.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.